Storm Therapeutics, which develops innovative drugs for cancer treatment, has secured $56 million in a Series C funding round aimed at financing. With this significant investment, the total funds raised by the company have exceeded $69 million.
Purpose of the Investment and About the Company
Founded in 2015 and focusing on RNA biology, Storm Therapeutics plans to use this new funding to advance the Phase 2 clinical trials of its drug STC-15. Additionally, it aims to finance clinical development programs investigating the drug's effects on other types of cancer.
The founders, Tony Kouzarides and Eric Miska, aim to create a biotechnology firm with the potential to revolutionize cancer treatment. They are particularly focused on RNA modifications that play a critical role in the processing of genetic information within cells.
METTL3 Enzyme and Treatment Strategy
One of the enzymes Storm Therapeutics focuses on is METTL3, which affects how cells interpret and express genetic information through chemical changes known as m6A. The disruption of this mechanism leads to uncontrolled proliferation of tumor cells in certain types of cancer. The STC-15 drug aims to reverse this situation; thus, weakening growth signals of tumor cells and initiating programmed cell death processes.
Storm Therapeutics particularly emphasizes hard-to-treat cancers like sarcoma, aiming to make a difference in the field by offering an innovative approach that targets genetic processes, unlike traditional treatment methods.